Ceritinib Fails Phase 0 Glioblastoma Trial
A clinical study shows ceritinib does not achieve the necessary drug penetration to treat recurrent glioblastoma tumors.
Updated on Oct. 16, 2026 in Cancer
Researchers conducting a phase 0 clinical trial on October 16, 2026, found that ceritinib fails to effectively penetrate brain tumor tissue. The drug was unable to achieve sufficient target engagement in patients with recurrent glioblastoma.
Why it matters
The study highlights how restricted free-drug penetration in intracranial lesions limits the effectiveness of this small-molecule inhibitor. Without target engagement, the drug cannot successfully act on the intended biological pathways.
The study recorded a median unbound fraction of 0.051% in contrast-enhancing tumor regions and 0.045% in nonenhancing tissue. These figures represent a sharp decline from the 1.4% median unbound fraction observed in human plasma.
The players
Ceritinib
Ceritinib is a small-molecule inhibitor that targets ALK, IGF1R, and FAK proteins within the body.
The details
Patients were administered oral ceritinib before undergoing surgical resection so researchers could evaluate target markers in the excised tissue. Analysis showed no statistically significant changes in proteins like pALK or pFAK, and cellular markers for proliferation remained identical to baseline levels.
Timeline
October 16, 2026: The study results were published.
Health Landscape
The failure of this ceritinib study illustrates the persistent challenges addressed by the phase 0 clinical trial framework for CNS drug delivery. This trial confirms a common hurdle in neuro-oncology where inhibitors fail to achieve sufficient tissue penetration.
Patients and clinicians are reminded that ceritinib is not an effective treatment option for recurrent glioblastoma due to its inability to reach tumor sites. This outcome underscores the importance of continued research into therapies capable of crossing the blood-brain barrier.
The takeaway
This trial reinforces the reality that laboratory success does not always translate to intracranial results in clinical settings. Future research must prioritize pharmacological agents specifically engineered to achieve higher free-drug concentrations within brain lesions.
Further reading
For more information on current developments in oncology, visit our Cancer section.
